In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines

Shigeki Ikubo, Nagio Takigawa, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Takuo Shibayama, Masakazu Chikamori, Keisuke Aoe, Akio Matsushita, Mine Harada

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The improvement of treatment outcome of small-cell lung cancer (SCLC), and search for new effective drugs and to overcome drug-resistance are essential. Materials and methods: We evaluated the cytotoxicity of antimicrotubule agents to seven human SCLC cell lines consisting of one cell line (SBC-3) established from a previously untreated patient as a representative of drug-sensitive cell line, three cell lines (SBC-2, SBC-4, and -7) derived from treated patients as representatives of intrinsic drug-resistant cell lines, and three drug-resistant sublines (SBC-3/ADM, SBC-3/ETP, and SBC-3/CDDP) selected by continuous exposure of the SBC-3 cell line to increasing concentrations of doxorubicin, etoposide, or cisplatin as representatives of acquired drug-resistant cell lines. Results: IC50 values for SBC-2, -3, -4, and -7 cells of antimicrotubule agents were markedly lower than those of doxorubicin, etoposide, and cisplatin. Both SBC-3/ADM and SBC-3/ETP subline were highly resistant to paclitaxel, docetaxel, vinorelbine, vincristine, vindesine, and vinblastine. However, an SBC-3/ADM subline was not fully cross-resistant to rhizoxin, and an SBC-3/ETP subline was as sensitive to rhizoxin as an SBC-3 cell line. A cisplatin-resistant subline, SBC-3/CDDP, showed no cross-resistance to the antimicrotubule agents. Conclusion: These results suggest that antimicrotubule agents are useful for SCLC, and rhizoxin may be particularly effective in the salvage treatment of refractory or relapsed patients.

Original languageEnglish
Pages (from-to)3985-3988
Number of pages4
JournalAnticancer Research
Volume19
Issue number5 B
Publication statusPublished - 1999

Fingerprint

Small Cell Lung Carcinoma
Cell Line
Cisplatin
Pharmaceutical Preparations
docetaxel
Etoposide
Doxorubicin
Vindesine
Patient Advocacy
Salvage Therapy
Vinblastine
In Vitro Techniques
Vincristine
Paclitaxel
Drug Resistance
Inhibitory Concentration 50

Keywords

  • Antimicrotubule agents
  • Drug resistance
  • MTT assay
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ikubo, S., Takigawa, N., Ueoka, H., Kiura, K., Tabata, M., Shibayama, T., ... Harada, M. (1999). In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines. Anticancer Research, 19(5 B), 3985-3988.

In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines. / Ikubo, Shigeki; Takigawa, Nagio; Ueoka, Hiroshi; Kiura, Katsuyuki; Tabata, Masahiro; Shibayama, Takuo; Chikamori, Masakazu; Aoe, Keisuke; Matsushita, Akio; Harada, Mine.

In: Anticancer Research, Vol. 19, No. 5 B, 1999, p. 3985-3988.

Research output: Contribution to journalArticle

Ikubo, S, Takigawa, N, Ueoka, H, Kiura, K, Tabata, M, Shibayama, T, Chikamori, M, Aoe, K, Matsushita, A & Harada, M 1999, 'In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines', Anticancer Research, vol. 19, no. 5 B, pp. 3985-3988.
Ikubo, Shigeki ; Takigawa, Nagio ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Tabata, Masahiro ; Shibayama, Takuo ; Chikamori, Masakazu ; Aoe, Keisuke ; Matsushita, Akio ; Harada, Mine. / In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines. In: Anticancer Research. 1999 ; Vol. 19, No. 5 B. pp. 3985-3988.
@article{e792202758704458832741c46106bd90,
title = "In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines",
abstract = "Background: The improvement of treatment outcome of small-cell lung cancer (SCLC), and search for new effective drugs and to overcome drug-resistance are essential. Materials and methods: We evaluated the cytotoxicity of antimicrotubule agents to seven human SCLC cell lines consisting of one cell line (SBC-3) established from a previously untreated patient as a representative of drug-sensitive cell line, three cell lines (SBC-2, SBC-4, and -7) derived from treated patients as representatives of intrinsic drug-resistant cell lines, and three drug-resistant sublines (SBC-3/ADM, SBC-3/ETP, and SBC-3/CDDP) selected by continuous exposure of the SBC-3 cell line to increasing concentrations of doxorubicin, etoposide, or cisplatin as representatives of acquired drug-resistant cell lines. Results: IC50 values for SBC-2, -3, -4, and -7 cells of antimicrotubule agents were markedly lower than those of doxorubicin, etoposide, and cisplatin. Both SBC-3/ADM and SBC-3/ETP subline were highly resistant to paclitaxel, docetaxel, vinorelbine, vincristine, vindesine, and vinblastine. However, an SBC-3/ADM subline was not fully cross-resistant to rhizoxin, and an SBC-3/ETP subline was as sensitive to rhizoxin as an SBC-3 cell line. A cisplatin-resistant subline, SBC-3/CDDP, showed no cross-resistance to the antimicrotubule agents. Conclusion: These results suggest that antimicrotubule agents are useful for SCLC, and rhizoxin may be particularly effective in the salvage treatment of refractory or relapsed patients.",
keywords = "Antimicrotubule agents, Drug resistance, MTT assay, Small-cell lung cancer",
author = "Shigeki Ikubo and Nagio Takigawa and Hiroshi Ueoka and Katsuyuki Kiura and Masahiro Tabata and Takuo Shibayama and Masakazu Chikamori and Keisuke Aoe and Akio Matsushita and Mine Harada",
year = "1999",
language = "English",
volume = "19",
pages = "3985--3988",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines

AU - Ikubo, Shigeki

AU - Takigawa, Nagio

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Shibayama, Takuo

AU - Chikamori, Masakazu

AU - Aoe, Keisuke

AU - Matsushita, Akio

AU - Harada, Mine

PY - 1999

Y1 - 1999

N2 - Background: The improvement of treatment outcome of small-cell lung cancer (SCLC), and search for new effective drugs and to overcome drug-resistance are essential. Materials and methods: We evaluated the cytotoxicity of antimicrotubule agents to seven human SCLC cell lines consisting of one cell line (SBC-3) established from a previously untreated patient as a representative of drug-sensitive cell line, three cell lines (SBC-2, SBC-4, and -7) derived from treated patients as representatives of intrinsic drug-resistant cell lines, and three drug-resistant sublines (SBC-3/ADM, SBC-3/ETP, and SBC-3/CDDP) selected by continuous exposure of the SBC-3 cell line to increasing concentrations of doxorubicin, etoposide, or cisplatin as representatives of acquired drug-resistant cell lines. Results: IC50 values for SBC-2, -3, -4, and -7 cells of antimicrotubule agents were markedly lower than those of doxorubicin, etoposide, and cisplatin. Both SBC-3/ADM and SBC-3/ETP subline were highly resistant to paclitaxel, docetaxel, vinorelbine, vincristine, vindesine, and vinblastine. However, an SBC-3/ADM subline was not fully cross-resistant to rhizoxin, and an SBC-3/ETP subline was as sensitive to rhizoxin as an SBC-3 cell line. A cisplatin-resistant subline, SBC-3/CDDP, showed no cross-resistance to the antimicrotubule agents. Conclusion: These results suggest that antimicrotubule agents are useful for SCLC, and rhizoxin may be particularly effective in the salvage treatment of refractory or relapsed patients.

AB - Background: The improvement of treatment outcome of small-cell lung cancer (SCLC), and search for new effective drugs and to overcome drug-resistance are essential. Materials and methods: We evaluated the cytotoxicity of antimicrotubule agents to seven human SCLC cell lines consisting of one cell line (SBC-3) established from a previously untreated patient as a representative of drug-sensitive cell line, three cell lines (SBC-2, SBC-4, and -7) derived from treated patients as representatives of intrinsic drug-resistant cell lines, and three drug-resistant sublines (SBC-3/ADM, SBC-3/ETP, and SBC-3/CDDP) selected by continuous exposure of the SBC-3 cell line to increasing concentrations of doxorubicin, etoposide, or cisplatin as representatives of acquired drug-resistant cell lines. Results: IC50 values for SBC-2, -3, -4, and -7 cells of antimicrotubule agents were markedly lower than those of doxorubicin, etoposide, and cisplatin. Both SBC-3/ADM and SBC-3/ETP subline were highly resistant to paclitaxel, docetaxel, vinorelbine, vincristine, vindesine, and vinblastine. However, an SBC-3/ADM subline was not fully cross-resistant to rhizoxin, and an SBC-3/ETP subline was as sensitive to rhizoxin as an SBC-3 cell line. A cisplatin-resistant subline, SBC-3/CDDP, showed no cross-resistance to the antimicrotubule agents. Conclusion: These results suggest that antimicrotubule agents are useful for SCLC, and rhizoxin may be particularly effective in the salvage treatment of refractory or relapsed patients.

KW - Antimicrotubule agents

KW - Drug resistance

KW - MTT assay

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0032806307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032806307&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 3985

EP - 3988

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -